Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

Brief summary (registry, in English)

This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.

What you commit to

• Study type: Observational
• Participants enrolled: 2759
• From 1 Jul 2019 to the primary completion date, 2 Sept 2025
• 302 sites in 21 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (302)

Sites in registry order. Pick your city on the disease page to sort them by distance.